Exenatide was the first GLP-1 drug, approved by the FDA in 2005 as Byetta. It is a synthetic version of exendin-4, a peptide first found in the venom of the Gila monster.[3][4] A once-weekly version, Bydureon, followed in 2012.[3] Brand-name Byetta and Bydureon BCise were discontinued in the US in October 2024,[13] and a generic referencing Byetta was approved in November 2024.[14]
What is exenatide?
In 1992, researchers isolated exendin-4, a 39-amino-acid peptide, from Gila monster venom. It activates the human GLP-1 receptor but resists the enzyme that breaks down natural GLP-1 within minutes.[4][5] Byetta’s half-life is about 2.4 hours, so it was injected twice daily before meals.[1]
Exenatide results
- Weekly vs twice daily (DURATION-1): once-weekly exenatide lowered HbA1c 1.9 points versus 1.5 for twice-daily.[6]
- Heart safety (EXSCEL): in 14,752 people, major cardiovascular events occurred in 11.4% versus 12.2% on placebo. It was shown to be safe but did not significantly reduce risk.[7]
- Youth: once-weekly exenatide lowered HbA1c 0.85 points more than placebo in young people with type 2 diabetes.[11]
Inside DURATION-1
DURATION-1 enrolled 295 adults with type 2 diabetes who were on no diabetes drugs or on one or more oral drugs. On average they weighed 102 kg, had an HbA1c of 8.3% and had lived with diabetes for 6.7 years. After 30 weeks, 77% on the weekly version reached an HbA1c of 7% or lower, versus 61% on twice-daily injections. The weekly version did not raise the risk of low blood sugar, and weight loss was similar with both.[6]
Inside EXSCEL
EXSCEL tested weekly exenatide 2 mg against placebo in 14,752 people with type 2 diabetes; 73% had prior cardiovascular disease. Over a median of 3.2 years, the hazard ratio for heart attack, stroke or cardiovascular death was 0.91. That met the test for safety but just missed showing a benefit. Rates of pancreatitis, pancreatic cancer, medullary thyroid cancer and serious adverse events did not differ significantly between groups.[7]
Parkinson’s disease
A small 2017 UK trial found people with Parkinson’s on exenatide had slightly better movement scores after a washout period.[8] But the larger phase 3 Exenatide-PD3 trial, published in 2025, found no evidence that exenatide slows the disease.[9] In June 2026, The Lancet issued an Expression of Concern about that paper; the reasons were not publicly detailed.[10]
Exenatide side effects
- Byetta: nausea 8% versus 0% on placebo as monotherapy; low blood sugar was common when combined with sulfonylureas (up to 35.7%).[1]
- No boxed warning for Byetta, but Bydureon BCise carries the thyroid C-cell tumor boxed warning.[1][2]
- Specific risks: antibodies that can reduce effectiveness, a rare immune-related drop in platelets, pancreatitis, kidney injury and gallbladder disease.[1][2]
- Bydureon BCise: injection-site nodules in 10.5% and nausea in 8.2%.[2]
Exenatide dosage
| Product | Dosing |
|---|---|
| Byetta | 5 mcg twice daily within an hour before morning and evening meals, increased to 10 mcg after 1 month[1] |
| Bydureon BCise | 2 mg once every 7 days[2] |
Byetta should never be taken after a meal.[1][15] It is injected within the 60 minutes before the morning and evening meals, or the two main meals at least 6 hours apart. A missed Byetta dose is skipped, and the next dose is taken as scheduled.[1]
Bydureon BCise could be taken at any time of day, with or without meals. A missed weekly dose could be taken if the next one was at least 3 days away.[2] A clinician sets the dose for any exenatide product.
Who should not use exenatide
- Byetta: not for people who have had a serious allergic reaction to exenatide, or a drop in platelets caused by an exenatide product. It is not recommended with severe kidney impairment (creatinine clearance below 30 mL/min) or end-stage kidney disease.[1]
- Bydureon BCise: not for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2), and not recommended when eGFR is below 45.[2]
- Both: not recommended for people with severe gastroparesis.[1][2] Byetta should not be combined with another exenatide product.[1]
Before its discontinuation, the Bydureon BCise label covered adults and children aged 10 and older with type 2 diabetes.[2]
Drug interactions and pregnancy
- Timing-sensitive pills: because exenatide slows stomach emptying, the Byetta label advises taking drugs such as oral contraceptives and antibiotics at least 1 hour before the injection.[1]
- Warfarin: there are reports of a raised INR (a blood-clotting test), sometimes with bleeding, so INR should be checked more often when exenatide is started or changed.[1]
- Insulin and sulfonylureas: doses may need lowering to avoid low blood sugar.[1]
- Pregnancy: data are limited. The label says to use it only if the benefit justifies the possible risk to the fetus.[1]
Questions to ask your clinician
- Is generic exenatide available and covered for me?
- Would a newer weekly GLP-1 drug with proven heart benefit suit me better?
- Does my kidney function allow exenatide?
- How should I time my other pills around the injection?
- Which signs of pancreatitis or unusual bleeding should make me call right away?
Exenatide vs newer GLP-1 drugs
Newer drugs such as liraglutide, dulaglutide, semaglutide and tirzepatide have largely replaced exenatide, with stronger effects and, for several, proven heart protection.
Exenatide around the world
In China, a generic exenatide was as effective as Byetta in 240 patients with type 2 diabetes.[12]
